Cargando…
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
BACKGROUND: As the number of indicated malignancies for which immune checkpoint inhibitor therapy such as pembrolizumab grows the descriptions of associated immune-related adverse events (irAEs) increases as well. On rare occasions immunotherapy can lead to development of Hemophagocytic Lymphohistio...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996173/ https://www.ncbi.nlm.nih.gov/pubmed/32025343 http://dx.doi.org/10.1186/s41199-020-0050-3 |